Physician
Ruxer, John
Ruxer, John was paid $274K by Medicaid between Jan 2018 and Dec 2024, across 24 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 31% of everything it billed.
33Billing provider infoRUXER, JOHN
PADUCAH, KY 42001
PADUCAH, KY 42001
33aNPI1205078987assigned 03/27/2009
33bProvider typeDiagnostic Radiology Physician
28Total paid$274K
24GClaims14,932
24DCodes billed24
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Diagnostic Radiology Physician providers in Kentucky
Rank by total paid#26 of 84
Median peer was paid$25K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 115 | $2K | |
| 2020 | 39 | $0.00 | |
| 2021 | 517 | $16K | |
| 2022 | 1,473 | $56K | |
| 2023 | 5,905 | $121K | |
| 2024incomplete | 6,883 | $79K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 31% | 1,896 | 1,758 | $86K |
| 62323 | 19% | 409 | 385 | $52K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 1,696 | 1,620 | $46K |
| L0651 | Lumbar-sacral orthosis, sagittal-coronal control, rigid shell(s)/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, anterior extends from symphysis pubis to xyphoid, produces intracavitary pressure to reduce load on the intervertebral discs, overall strength is provided by overlapping rigid material and stabilizing closures, includes straps, closures, may include soft interface, pendulous abdomen design, prefabricated, off-the-shelf | 12% | 58 | 46 | $33K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 9.6% | 877 | 821 | $26K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 3.8% | 128 | 125 | $10K |
| 64635 | 1.9% | 24 | 15 | $5K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 1.2% | 434 | 408 | $3K |
| 99406 | 1.1% | 328 | 302 | $3K | |
| 64636 | <1% | 25 | 14 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 55 | 49 | $2K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 30 | 29 | $2K |
12 more codes
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 12 | $532.39 |
| 99490 | Ccm add 20min | <1% | 66 | $434.22 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 131 | $228.73 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 74 | $64.92 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 1,096 | $0.00 |
| G9500 | Radiation exposure indices documented in final report for procedure using fluoroscopy | 0% | 984 | $0.00 |
| G8539 | Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment | 0% | 1,990 | $0.00 |
| 3725F | 0% | 579 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 715 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 1,885 | $0.00 |
| 3085F | 0% | 1,113 | $0.00 | |
| 98960 | 0% | 327 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.